Mariusz Milik

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.0kcitations37works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Structure and Dynamics(9), Cancer Mechanisms and Therapy(6), Computational Drug Discovery Methods(5), Lipid Membrane Structure and Behavior(5), PI3K/AKT/mTOR signaling in cancer(5)

Publications37 total

Design and Synthesis of New Quinazolin-4-one Derivatives with Negative mGlu7 Receptor Modulation Activity and Antipsychotic-Like Properties
International Journal of Molecular Sciences·2023· 8 citedOpen Access
Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock
European Journal of Medicinal Chemistry·2020· 6 citedOpen Access
How to design potent and selective DYRK1B inhibitors? Molecular modeling study
Journal of Molecular Modeling·2019· 9 cited
5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2018· 8 citedOpen Access
Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry·2017· 69 cited
Abstract C194: Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in cancer
Molecular Cancer Therapeutics·2015
Abstract 755: Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancer
Cancer Research·2014
Abstract A49: Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases
Cancer Research·2013
Abstract 2160: Development of selective MELK kinase inhibitors for cancer treatments.
Cancer Research·2013
Abstract 3245: Identification of potent, dual PIM/FLT3 kinase inhibitors for AML treatment.
Cancer Research·2013· 1 cited
Abstract 696: Development of selective CDK8 inhibitors for colorectal cancer and mantle cell lymphoma treatment.
Cancer Research·2013
516 Development of Selective PIM Kinase Inhibitors for Cancer Treatment
European Journal of Cancer·2012
518 Development of Selective CDK8 Inhibitors for Colorectal Cancer Treatment
European Journal of Cancer·2012
Abstract 3845: Antitumor activity of SEL120: An orally available dual inhibitors of Haspin/CDK9, for standalone and combination therapy with AuroraB inhibitors in solid tumors and hematopoietic malignancies
Cancer Research·2012· 3 cited
Abstract 2826: Preclinical development of a Pim kinase inhibitor for cancer treatment
Cancer Research·2012· 1 cited
Abstract A243: Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors.
Molecular Cancer Therapeutics·2011
Abstract B242: Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase for standalone and combination therapy with AuroraB inhibitors in colorectal cancer.
Molecular Cancer Therapeutics·2011
SPREAD—exploiting chemical features that cause differential activity behavior
Statistical Analysis and Data Mining The ASA Data Science Journal·2009· 1 cited
Mapping Adverse Drug Reactions in Chemical Space
Journal of Medicinal Chemistry·2009· 157 cited
Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis
Journal of Chemical Information and Modeling·2009· 154 cited
page 1 of 2Next →

Frequent Co-authors

Krzysztof Brzózka(16), Jeffrey Skolnick(11), Tomasz Rzymski(11), Renata Windak(10), Agnieszka Dreas(8), Adrian Zarębski(8), Ewa Trębacz(7), Andrzej Koliński(6), Karolina Krawczyńska(6), Małgorzata Żurawska(6), Agnieszka Szamborska‐Gbur(5), Marek Chołody(5), Katarzyna Prymula(5), Wojciech Czardybon(5), Josef Scheiber(4), Jeremy L. Jenkins(4), Sai Chetan K. Sukuru(4), Andreas Bender(4), Meir Glick(4), John W. Davies(4)